Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine
Retrieved on:
Thursday, August 5, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Alpha, Phase II, Volunteering, Research, Chief executive officer, Beta, Vaccine, DPH, COVID-19, University Medical Center Groningen, Seroconversion, Coronavirus, Disease, Temperature, SmartCell Technology, Martek Biosciences Corporation, Plant, Ageing, Infection, RBD, GMP, Contract research organization, Therapy, Health, Patient, Autoimmune disease, Merck, Merck & Co., RNA transfection, Hospital, Safety, CRO, Education, Pharmaceutical industry, the Phase II clinical trial, AKS-452, Akston Biosciences, TRACER, University Medical Center Groningen, THE PHASE II CLINICAL TRIAL, AKS-452, AKSTON BIOSCIENCES, TRACER, UNIVERSITY MEDICAL CENTER GRONINGEN
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Key Points:
- Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
- The trial is managed by TRACER Europe B.V., a Contract Research Organization (CRO) specializing in fast-track clinical trials.
- From Phase I, we know the AKS-452 showed limited side-effects, comparable to the current registered anti-COVID-19 vaccines, said Schelto Kruijff, M.D.
- Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.